

Rosmantuzumab

Cat. No.:	HY-P99401
CAS No.:	1684393-04-1
Target:	Others
Pathway:	Others
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.

BIOLOGICAL ACTIVITY

Description	Rosmantuzumab (OMP-131R10) is an anti-R-spondin 3 (RSPO3) humanized monoclonal antibody. Rosmantuzumab can be used for the research of advanced telapsed and refractory solid tumors ^[1] .								
In Vivo	<p>Rosmantuzumab (25 mg/kg; i.p., once a week for 4 weeks) significantly protects the animals from developing liver fibrosis^[1]. Rosmantuzumab (25 mg/kg; i.p., once for two weeks, for total 6 weeks) significantly inhibits skin thickness, collagen deposition, and number of α-SMA positive cells in bleomycin-induced lung fibrosis mouse models^[1]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p> <table border="1" style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 30%;">Animal Model:</td> <td>Male C57B1/6J CCl4 liver fibrosis mouse models^[1]</td> </tr> <tr> <td>Dosage:</td> <td>25 mg/kg</td> </tr> <tr> <td>Administration:</td> <td>Intraperitoneal injection; 25 mg/kg, once a week for 4 weeks</td> </tr> <tr> <td>Result:</td> <td>Significantly decreased collagen I and collagen III mRNAs, and inhibits β-catenin cytoplasmic and nuclear translocation.</td> </tr> </table>	Animal Model:	Male C57B1/6J CCl4 liver fibrosis mouse models ^[1]	Dosage:	25 mg/kg	Administration:	Intraperitoneal injection; 25 mg/kg, once a week for 4 weeks	Result:	Significantly decreased collagen I and collagen III mRNAs, and inhibits β -catenin cytoplasmic and nuclear translocation.
Animal Model:	Male C57B1/6J CCl4 liver fibrosis mouse models ^[1]								
Dosage:	25 mg/kg								
Administration:	Intraperitoneal injection; 25 mg/kg, once a week for 4 weeks								
Result:	Significantly decreased collagen I and collagen III mRNAs, and inhibits β -catenin cytoplasmic and nuclear translocation.								

REFERENCES

[1]. Zhang M, et al. Targeting the Wnt signaling pathway through R-spondin 3 identifies an anti-fibrosis treatment strategy for multiple organs. PLoS One. 2020 Mar 11;15(3):e0229445.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA